Harbour BioMed presented phase I data showing favorable safety and preliminary efficacy for HBM1020, a potential new treatment for resistant solid tumors, at ESMO Congress 2024.

Harbour BioMed presented new clinical data on HBM1020, a fully human anti-B7H7/HHLA2 monoclonal antibody, at ESMO Congress 2024. Results from a phase I trial indicated favorable safety and tolerability across all doses, with most adverse events being mild. The drug demonstrated a two-week elimination half-life and showed preliminary efficacy, with 46.7% of patients achieving stable disease. HBM1020 may offer a new treatment option for patients with advanced solid tumors, especially those resistant to PD-L1 therapies.

September 14, 2024
5 Articles

Further Reading